James Huang bought $670K of Atara Biotherapeutics (ATRA)
Executed Aug 15 2025, disclosed Aug 20 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 19 2025), the stock returned +0.5% (delay-adjusted); from the execution session (Aug 15 2025), +1.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
James Huang (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in Atara Biotherapeutics, Inc. (ATRA). Across 2 priced purchase filings, the average 21-session return was -4.9% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of CNTB (1,160,000 sh × $3.45, as filed), executed Mar 31.
Healthcare · Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the U…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→313,446 sh × $10.10
Exec May 7
Filed May 11 · 5:30 PM ET ATRASALE Atara Biotherapeutics, Inc. $489K
80,554 sh × $6.07
Exec Jan 12
Filed Jan 14 · 5:30 PM ET ATRAPURCHASE Atara Biotherapeutics, Inc. $186K
19,335 sh × $9.64
Exec Jul 17 2025
Filed Jul 21 2025 · 9:00 AM ET